JLL vs SBRA
Jones Lang LaSalle vs Sabra Health Care REIT — AI-powered side-by-side comparison
JLL
Jones Lang LaSalle
68
Buy
VS
SBRA
Sabra Health Care REIT
50
Watch
| Metric | JLL | SBRA |
|---|
| AI Score |
68
|
50
|
| Price |
$392.77
|
$20.83
|
| P/E Ratio |
18.45×
|
78.86×
|
| ROE |
10.6%
|
5.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
89.6%
|
72.6%
|
| Debt / Equity |
0.34×
|
0.96×
|
| Dividend Yield |
0.0%
|
5.8%
|
| RSI (14) |
74.0
|
60.0
|
| Beta |
1.24
|
0.643
|
| Expected Upside |
—
|
+1.1%
|
AI Committee View
Current Innellis committee reasoning for JLL versus SBRA.
JLL leads by 18 points.
JLL scores 68/100 (Buy) versus SBRA at 50/100 (Watch).
JLL Committee View
100% agreement
6 analysts
The primary driver is low leverage (debt-to-equity 0.22) -- balance sheet can absorb a shock. The main limiting factor is sector concentration is already high (hhi 3068.56). The committee is constructive but not yet at full conviction.
Bull Case
- EPS growing 79.2% YoY — Growth
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- RSI at 70 is in overbought territory — Technical
- Weekly RSI at 80 -- overbought on the larger timeframe too — Technical
SBRA Committee View
50% agreement
4 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case. Growth Analyst remains cautious — 4 consecutive earnings misses -- execution concerns. This disagreement is itself the signal — the setup is not clean in either direction.
Bear Case
- 4 consecutive earnings misses -- execution concerns — Growth
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
- MACD histogram negative -- bearish momentum — Technical